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AIMS
Liver-enriched microRNA-122 (miR-122) is a novel circulating biomarker for drug-induced liver injury (DILI). To date, miR-122 has
been measured in serum or plasma venous samples. If miR-122 could be measured in capillary blood obtained from a finger prick
it would facilitate point-of-care testing, such as in resource-limited settings that have a high burden of DILI.
METHODS
In this study, in healthy subjects, miR-122 was measured by polymerase chain reaction in three capillary blood drops taken from
different fingers and in venous blood and plasma (n = 20). miR-122 was also measured in capillary blood obtained from patients
with DILI (n = 8).
RESULTS
Circulating miR-122 could be readily measured in a capillary blood drop in healthy volunteers with a median (interquartile range)
cycle threshold (Ct) of 32.6 (31.1–34.2). The coefficient of variation for intraindividual variability across replicate blood drops was
49.9%. Capillary miR-122 faithfully reflected the concentration in venous blood and plasma (Pearson R = 0.89, P < 0.0001; 0.88,
P < 0.0001, respectively). miR-122 was 86-fold higher in DILI patients [median value 1.0 × 108 (interquartile range 1.89 × 107–
3.04 × 109) copies/blood drop] compared to healthy subjects [1.85 × 106 (4.92 × 105–5.88 × 106) copies/blood drop]. Receiver
operator characteristic analysis demonstrated that capillary miR-122 sensitively and specifically reported DILI (area under the
curve: 0.96, P = 0.0002).
CONCLUSION
This work supports the potential use of miR-122 as biomarker of human DILI when measured in a capillary blood drop. With
development across DILI aetiologies, this could be used by novel point-of-care technologies to produce aminimally invasive, near-
patient, diagnostic test.
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WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• Drug-induced liver injury (DILI) is a major healthcare challenge in western countries and in resource-limited settings.
• microRNA-122 (miR-122) has substantial promise as a sensitive and specific biomarker of hepatocyte injury when
measured in venous samples.
WHAT THIS STUDY ADDS
• miR-122 can be quantified reliably in a capillary blood drop from a finger prick.
• Capillary miR-122 faithfully reflects the plasma and venous whole blood concentration.
• Capillary miR-122 can identify patients with DILI with high sensitivity and specificity.
• If combined with a novel point-of-care detection platform, capillary miR-122 could allow near patient testing for DILI.
Introduction
Drug-induced liver injury (DILI) presents a major burden to
clinical medicine and is a common cause of drug failure
during clinical development [1]. In western clinical medicine,
about half of the cases of acute liver failure are caused by DILI
[2]. In the developing world, cotreatment of human
immunodeficiency virus (HIV) and tuberculosis (TB) is a
major cause of DILI. Globally, an estimated 37 million people
are HIV-positive, with eastern and southern Africa carrying
the highest burden with an estimated 19 million people
infected [3]. The South African, TB incidence is particularly
high; new diagnoses being 834 per 100 000 per annum [4].
TB prevalence is high in people coinfected with HIV, with
42% of HIV-positive TB cases receiving both TB and
antiretroviral treatment [5]. DILI complicates TB treatment
in up to 33% of cases [6], and in South Africa the in-hospital
mortality from DILI has been reported to be around 30% [5].
MicroRNAs (miRNAs) are small (~22 nucleotides long)
nonprotein-coding RNAs involved in post-transcriptional
gene regulation [7]. In the circulation, miRNAs are protected
from degradation by binding to RNA protein complexes
(such as argonaute 2) and high-density lipoproteins, and
being encapsulated in extracellular vesicles such as exosomes
[8, 9]. AsmiRNAs are amplifiable and some are tissue enriched
[10], they have emerged as a reservoir for the discovery of
biomarkers that report organ injury [11].
The liver enriched miRNA-122 (miR-122) is a circulating
biomarker of DILI. miR-122 is released into the circulation
when hepatocytes are injured and is a translational safety
biomarker across zebrafish [12], rodents [13] and humans
[14–16]. In humans, miR-122 is around 100-fold higher in
paracetamol overdose patients with DILI compared to those
patients without liver injury [17] and is able to report DILI
soon after overdose when serum alanine transaminase (ALT)
activity is still in the normal range [14, 15, 18]. Circulating
miR-122 is not DILI specific but is specific for hepatocyte
injury. It is also increased in patients with cholestyramine-
induced liver injury [19], ischemic hepatitis [20], viral
hepatitis [21] and cholestatic liver injury [22]. In these
published studies serum or plasma venous samples have been
analysed in specialist laboratories with time-consuming and
expensive kits. There is an unmet need for assays that can
rapidly and accurately measure miRNA at the point-of-care
(POC) [23]. Ideally, a POC assay would measure miR-122 in
a single blood drop from a finger prick, be affordable for use
in resource-limited settings and suitable for use near, or
actually in, a patient’s home [24]. Such an assay could provide
an early signal of DILI in patients at elevated risk, for instance,
following prescription of antimicrobials with a significant
DILI liability [25–27]. With development, serial monitoring
of miR-122 could improve patient safety by allowing
medication change before life-threatening liver failure
develops and by supporting safe reintroduction of treatment
after interruption. In commercial drug development,
measurement of miR-122 using a finger prick could reduce
the need for venepuncture, which is especially advantageous
in certain groups such as children and when multiple serial
measurements in the same person are required.
The aims of this study were to determine if miR-122 can
be measured in a capillary blood drop from a finger prick
and to compare the concentration with venous blood and
plasma; to assess the intraindividual variability of capillary
miR-122 concentration and to establish proof of concept as
to whether capillary miR-122 can report DILI in patients.
Material and methods
The study was approved by the research ethics committee
(East Midlands – Nottingham 1 Research Ethics Committee)
andperformed in accordancewith theDeclarationofHelsinki.
Informed consent was obtained from all participants.
Healthy volunteers
Healthy volunteers were eligible if they had no history of liver
disease, were taking no medications and were willing to give
blood samples by venepuncture and finger prick.
Drug-induced liver injury patients
A total of eight adult patients (age 24–82 years) admitted to
the Royal Infirmary of Edinburgh, UK with DILI were entered
into the study. In each patient, causality of liver injury was
scored as definitive by the Roussel Uclaf Causality Assessment
Method [28].
Blood collection
Blood was collected in EDTA tubes by venepuncture.
Immediately, a 50 μL aliquot was collected in 1 mL of Qiazol
(Qiagen, Venlo, Netherlands) for whole blood analysis. The
remaining blood was centrifuged at 11 000 × g for 15 min at
4°C after which the supernatant was separated into aliquots
and frozen at –80°C until miRNA extraction.
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Three finger-prick blood drops (BD1: index finger, BD2:
middle finger, BD3: ring finger) per healthy volunteer were
obtained using disposable lancets that are used in routine
clinical practice for glucosemeasurement (Accu-Chek, Roche,
Basel, Switzerland – adjustable depth settings 1.8 mm). In
DILI patients, one blood drop from the index finger was
collected. After blood drop collection, Qiazol (1 ml) was
added to each sample. All samples were stored at –80°C until
analysis.
MicroRNA extraction
MicroRNA was extracted using miRNeasy Serum/Plasma kit
(Qiagen), following the manufacturer’s instructions. For
venous blood and plasma, 50 μl of sample was used in
combination with 150 μl nuclease free water. For capillary
blood, 200 μl nuclease free water was added to the Qiazol
containing each blood drop.
Real-time polymerase chain reaction
From each sample, 2.5 μl of RNA eluate was reverse
transcribed into cDNA using the miScript II RT Kit (Qiagen)
following manufacturer’s instructions. The synthesized
cDNA was 5-fold diluted and used for cDNA template in
combination with the miScript SYBR Green polymerase
chain reaction (PCR) Kit (Qiagen) using the specific miScript
assays (Qiagen). Real-time PCR was performed in duplicate
on a Light Cycler 480 (Roche) using the recommended
miScript cycling parameters.
Absolute quantitation of miRNA was achieved by
generating a standard curve using synthetic target. Standard
curves were generated by reverse transcribing known
concentrations of miScript miRNA mimics (Qiagen, Venlo,
The Netherlands) in 0.1X TE buffer spiked with 10 ng μl–1
Poly-C (Sigma–Aldrich, Gillingham, UK). The resulting cDNA
was measured using serial dilutions on three different plates
on 3 different days to demonstrate minimal variability
[interassay coefficient of variation (CV): 3.4%]. The calibra-
tion curve was linear in the cycle threshold (Ct) range of
20.0–36.1. A Ct value of 37.1 was obtained in water control.
Statistical analysis
Statistical differences, correlations and receiver operator
characteristic (ROC) curve analyses were performed using
Graphpad Prism (GraphPad Software, La Jolla California,
USA). Nominal statistical significance was set at P < 0.05.
Table 1
Copy numbers of capillary miR-122 per blood drop (BD1: index finger; BD2: middle finger; BD3: ring finger) in healthy volunteers. The coefficient
of variation (CV) across the three blood drops is presented
Healthy volunteer
number BD1 (copy/drop) BD2 (copy/drop) BD3 (copy/drop) CV (%)
1 0.45 × 106 0.40 × 106 1.53 × 106 81.13
2 3.39 × 106 11.5 × 106 4.11 × 106 71.14
3 0.29 × 106 0.41 × 106 0.11 × 106 54.52
4 0.24 × 106 0.11 × 105 0.20 × 106 37.15
5 0.59 × 106 0.17 × 106 0.42 × 106 54.17
6 1.25 × 106 0.91 × 106 0.69 × 106 29.85
7 0.11 × 106 0.20 × 106 0.28 × 106 43.24
8 2.85 × 106 5.20 × 106 1.18 × 106 65.70
9 1.53 × 106 0.89 × 106 0.69 × 106 42.28
10 0.29 × 106 0.23 × 106 4.45 × 106 146.1
11 0.13 × 106 0.14 × 106 0.19 × 106 20.47
12 1.37 × 106 2.81 × 106 1.93 × 106 35.53
13 2.09 × 106 0.64 × 106 1.20 × 106 56.18
14 1.53 × 106 6.40 × 106 5.52 × 106 57.85
15 5.06 × 106 9.52 × 106 8.79 × 106 30.74
16 10.6 × 106 9.07 × 106 10.3 × 106 8.00
17 7.61 × 106 9.37 × 106 5.70 × 106 24.26
18 1.81 × 106 3.00 × 106 5.18 × 106 51.21
19 4.70 × 106 2.69 × 106 2.79 × 106 33.44
20 36.6 × 106 36.3 × 106 10.3 × 106 54.38
Mean 4.12 × 106 5.00 × 106 3.28 × 106 49.87
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Results
Capillary miR-122 can be measured in a finger
prick blood drop
A total of 20 adults (14 females, median age 24 years; range
21–31 years) were recruited to this study. First it was
determined whether a capillary blood drop yields sufficient
miR-122 for robust quantification. Capillary blood Ct
values (obtained by quantitative PCR) were all within the
linear range of the calibration curve [mean (range) 32.6
(29.1–35.4)]. Copy numbers of miR-122 per blood drop in
the healthy controls are presented in Table 1. Across the
replicate drops fromdifferent fingers themeanCV (± standard
deviation) was 49.9 ± 28.9%. The CV ± standard deviation of
duplicate PCR measurements of the same blood drop was
0.94 ± 1.29%.
Capillary miR-122 correlates with venous
blood and plasma
Across the healthy volunteers, the relationship between copy
numbers of miR-122 per blood drop and copy numbers of
miR-122 per mL of venous blood and plasmawas determined.
Copy number of miR-122 per blood drop significantly
correlated with miR-122 measured in venous blood and
plasma (P< 0.0001, Figure 1A, B). The correlation coefficients
(R2) were 0.80 and 0.78 and the Pearson R values [95%
confidence interval (CI)] were 0.89 (0.75–0.96) and 0.88
(0.72–0.95), both P < 0.0001, in venous blood and plasma,
respectively. As would be expected there was a significant
correlation between venous blood and plasma miR122
(Figure 1C).
Liver-enriched miRNA-122 is higher in ALI
patients
Capillary miR-122 was measured in blood drop samples
obtained from patients with DILI (n = 8) and compared with
healthy volunteers (n = 20). Clinical parameters of the DILI
patient cohort are summarized in Table 2, along with their
capillary miR-122 concentrations. In the single case of
nonparacetamol DILI (induced by nitrofurantion) other
causes of liver disease such as viral hepatitis (A–E) were
excluded. miR-122 was increased 86 fold in DILI patients
[median 1.58 × 108 (interquartile range 4.67 × 106–4.51 ×
109) copies/blood drop] compared to healthy volunteers
[1.85 × 106 (1.53 × 105–2.77 × 107) copies/blood drop]
P = 0.004 (Figure 2). ROC analysis was performed to determine
the sensitivity and specificity of miR-122 for detecting DILI
(Figure 3). Capillary miR-122 had high sensitivity and
specificity (area under the curve; 0.96 (95%CI 0.89–1.04),
P = 0.0002, sensitivity: 86% at 90% specificity).
Discussion
This study has demonstrated, for the first time, that capillary
miR-122 can be measured in a single blood drop to report
DILI. This facilitates point-of-care measurement out with
hospital, such as in the developing world where the burden
of DILI is substantial.
Figure 1
Scatter graphs. Correlation between copy numbers of miR-122 per
mL (A) venous blood or (B) plasma and copy numbers of miR-122
per capillary blood drop. (C) correlation between copy numbers of
miR-122 per mL venous blood and plasma in each healthy volunteer
(n = 20). Pearson R values are 0.89 (P < 0.0001), 0.88 (P < 0.0001)
and 0.92 (P < 0.0001), respectively (Pearson’s correlation test).
Blood drop values represent the mean copy number measured in
three drops, error bars represent standard errors of the mean
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Whenmeasured in capillary blood, the miR-122 Ct values
were all within the quantifiable range of the PCR assay that
had a linear calibration curve up to a Ct of 36. Intraindividual
variability was tested by comparing three different blood
drops taken from the same volunteer and resulted in an
average CV of around 50%. Respectively, the intra-assay and
interassay CVs of the PCR assay were only 0.94% and 3.4%,
therefore the CV across the blood drops probably represents
the variable volumes of the blood drops obtained during the
collection procedure. The intraindividual CV of blood drop
volume obtained from a finger has been reported to be 83%
[29]. This is comparable to the intraindividual CV of miR-
122 measured in our study. In a future POC assay, the
variability of sample volume could be reduced by automated
microchip sample processing technologies [30, 31] as already
applied in test strips for international normalized ratio (INR)
POC testing in the context of warfarin dosing [32].
Furthermore, as the circulating concentration of miR-122
increases up to a 100 fold in DILI patients [14], a CV of 50%
would be expected to have little effect on the detection of
DILI.
The concentration of capillarymiR-122measured in blood
drops strongly correlated with blood and plasma obtained
from venepuncture. This provides reassurance that our data
reflect circulating concentrations. Furthermore, capillary
miR-122was significantly higher in blood drops frompatients
with DILI compared to healthy volunteers with amedian fold
increase of 86 and a ROC curve area under the curve of 0.96.
These data confirm that the dynamic changes and the
sensitivity to report DILI is similar between blood drops and
earlier reported results from serum/plasma venous samples
[14, 15]. A challenge in using circulating miRNAs as
Table 2
Clinical parameters of the patient cohort with drug-induced liver injury (DILI).
Patient Age (years) Sex
ALT
activity
(U l–1) INR
Serum
creatinine
(μmol l–1)
ALP
activity
(U/L)
Bilirubin
(μmol dl–1) Aetiology
Copies miR-
122/ drop
1 82 F 3475 2 50 74 29 Paracetamol 1.58 × 108
2 44 F 10 543 6.9 47 101 106 Paracetamol 4.51 × 109
3 54 F 1210 8.9 66 236 162 Nitrofurantoin 4.09 × 107
4 24 F 1608 1.4 79 239 224 Paracetamol 1.58 × 108
5 29 M 1143 1.7 52 43 17 Paracetamol 5.64 × 107
6 25 M 1653 1.9 72 147 58 Paracetamol 1.66 × 109
7 45 M 1131 1.5 65 79 34 Paracetamol 3.50 × 109
8 35 M 1101 1.8 57 141 32 Paracetamol 1.16 × 107
ALT, alanine aminotransferase; INR, international normalized ratio; serum creatinine; ALP, alkaline phosphatise; bilirubin and aetiology of DILI are
presented
Figure 3
Receiver operator characteristic curve analysis with respect to blood
drop miR-122 as a discriminator of drug-induced liver injury patients
from healthy volunteers. Area under the curve (AUC), statistical
significance and sensitivity (SENS) at 90% specificity (95%CI) are
presented
Figure 2
Copy number of miR-122 per blood drop from healthy volunteers
(n = 20) and drug-induced liver injury patients (n = 8). Data are
presented as a Tukey plot. In healthy volunteers, the mean copy
number measured in three drops was used
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biomarkers for human pathology is that the contribution of
different tissues to the circulating pool is often unknown.
Most miRNAs are expressed in multiple cell types, by contrast
miR-122 is highly specific for the liver [33, 34]. miR-122 is not
expressed in platelets, T-cells, B-cells, granulocytes or
erythrocytes, which contain a wide variety of other miRNA
species [35]. This makes miR-122 suitable for accurate
measurement in whole blood without need for plasma or
serum isolation.
There is an urgent need for improved DILI monitoring in
the developing world where cotreatment of HIV and TB is a
common cause [5]. However, despite the need, DILI
monitoring in resource-limited settings is often restricted by
practical concerns. The requirement for expensive tools and
highly trained technicians can mean testing is only done in
centralized or regional laboratories [24]. Moreover, many
patients undergoing TB treatment in resource-limited
settings have a negative association with venepuncture itself,
do not have a primary care physician and do not value regular
visits to a health care professional for health maintenance,
which reduces potential participation in DILI monitoring
[36]. A rapid POC test for measuring miR-122 from a single
blood drop would mean that the patient undergoing TB
and/or HIV treatment could use the assay at home (or near
home). This study has demonstrated that a blood drop can
be used as the matrix to measure miR-122. Recently,
substantial effort has been spent in developing highly
sensitive, rapid, reliable and low-cost methods for measuring
miRNAs in minimal sample volumes. Electrochemical DNA
hybridization sensors have potential as detection techni-
ques in a POC test because this technology can detect
specific miRNAs in the attomolar range without PCR
amplification [37]. Other promising miRNA detection
methods include nanoparticle-based optical technologies
[38], surface plasmon resonance [39, 40] and amplification-
free fluorescence-based assays [41, 42]. As miR-122 is a
relatively high-concentration, organ-specific, circulating
miRNA with a large dynamic range in disease it represents
an ideal target for assay development with line of sight on
a commercial product tackling a global health need.
This is an early phase proof of concept study that
predominately used paracetamol toxicity as the model of
DILI (seven of eight patients). Work is now required to
determine whether capillary miR-122 has clinical utility in
DILI caused by other drugs, especially antimicrobials. In
conclusion, this work supports the potential use of miR-122
as biomarker of human DILI when measured in a blood drop
from a finger prick. This could be used by novel POC
technologies to produce a minimally invasive, near patient,
diagnostic for DILI that has enhanced sensitivity and
specificity compared to current tests.
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